PPIDT00223
Drug Information
| Name | Mepolizumab |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB06612 |
| Type | biotech |
| Indication | Mepolizumab is an anti-IL-5 IgG1 kappa monoclonal antibody indicated as an add-on maintenance treatment in patients aged six years and older with severe eosinophilic asthma and as a treatment in adult patients for eosinophilic granulomatosis with polyangiitis (EGPA). Mepolizumab is also indicated for the treatment of hypereosinophilic syndrome (HES) in patients aged 12 and older in whom eosinophilia is present for at least six months without an identifiable non-hematologic secondary cause.[L16518] Mepolizumab is additionally indicated as an add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in patients ≥18 years old with inadequate response to nasal corticosteroids.[L16518] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection | Subcutaneous |
100 mg
|
| Injection, powder, for solution | Subcutaneous |
100 mg/1mL
|
| Injection, powder, for solution | Subcutaneous |
100 MG
|
| Injection, solution | Parenteral; Subcutaneous |
100 MG
|
| Injection, solution | Parenteral; Subcutaneous |
40 mg
|
| Injection, solution | Subcutaneous |
100 mg
|
| Injection, solution | Subcutaneous |
100 mg/1mL
|
| Injection, solution | Subcutaneous |
40 mg/0.4mL
|
| Injection, solution | Subcutaneous |
40 mg
|
| Powder, for solution | Subcutaneous |
100 mg / vial
|
| Solution | Subcutaneous |
100 mg / mL
|
| Solution | Subcutaneous |
40 mg / 0.4 mL
|
| Solution | Subcutaneous |
40.000 mg
|
| Injection, powder, for solution | Subcutaneous |
10000000 mg
|
| Solution | Subcutaneous |
100 mg/ml
|
| Injection, powder, lyophilized, for solution | Subcutaneous |
100 mg
|
| Injection, solution | Subcutaneous |
100 mg/ml
|
| Solution | Subcutaneous |
10000000 mg
|
| Injection, powder, for solution | Subcutaneous |
100 mg/1vial
|